TEM250425C44000
- 9.00
- 0.000.00%
Tempus AI Newsroom
Catalyst Watch: Powell Presser, AMD Earnings, IBM Event, and Lions Gate Splits in Two
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
Jim Cramer: Sunrun Had 'Bad Couple Of Quarters,' ExlService Holdings Is 'Solid'
Investing Pros Haven't Been This Worried About the Stock Market in at Least 28 Years, Our Exclusive Poll Finds
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
Express News | Tempus Time Network Expands Support of Phase I Clinical Trials to Accelerate Activation and Enrollment
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
Earnings Preview: Tempus AI to Report Financial Results Post-market on May 06
Tempus AI Publishes XF+ Assay Study Results in Journal of Molecular Diagnostics
Tempus AI Announces Publication Of Its Study 'Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy' In The Journal of Molecular Diagnostics
BTIG Maintains Tempus AI(TEM.US) With Buy Rating, Maintains Target Price $60
Tempus AI Inc Class A Call Volume Above Normal and Directionally Bullish
Analysts Split on High-Stakes 'Call Option' for Tempus AI Stock (TEM)
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
Will the US Stock Market's Rebound Ignite Your Next Trade?
Why Tempus AI Inc. (TEM) Soared Last Week
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, IRhythm Technologies and SOPHiA GENETICS
TD Cowen Maintains Tempus AI(TEM.US) With Buy Rating, Cuts Target Price to $62
Press Release: Tempus to Report First Quarter 2025 Financial Results on May 6